Gothenburg 27th of March – Simsen Diagnostics is excited to announce their selection for Business Sweden’s prestigious Catalyst program, which is a significant step in the company’s journey towards international expansion. The Catalyst program, designed for the most innovative and…
Simsen Diagnostics AB, a leader in cancer monitoring, is pleased to announce a collaboration with Professor Peter Naredi and his research group at Sahlgrenska University Hospital. This partnership focuses on enhancing the detection and monitoring of pancreatic cancer, using Simsen…
Göteborg, 2024-01-19 – Simsen Diagnostics, a pioneer in cancer monitoring solutions, today announced that Gustav Johansson will be stepping down from his role as CEO from April 1, 2024. Under his leadership, Simsen Diagnostics has successfully transitioned from an academic…
Biotech company Neogap and cancer diagnostics company Simsen Diagnostics have initiated a collaboration aimed at improving personalized cancer diagnostics by examining circulating tumor DNA in the blood of patients participating in Neogap’s Phase I/II clinical trial. The goal is to…
Bioteknikbolaget Neogap och cancerdiagnostikbolaget Simsen Diagnostics har inlett ett samarbete inriktat på att förbättra individanpassad cancerdiagnostik genom att undersöka cirkulerande tumör-DNA i blodet hos patienter som deltar i Neogaps kliniska fas I Målet är att utveckla mer precisa och effektiva…
Gothenburg 2022-12-06 Simsen Diagnostics AB and Oncorena AB have entered into an agreement, where Simsen Diagnostics will measure circulating tumor DNA in Oncorena’s clinical phase I-II kidney cancer study. Simsen Diagnostics will design individualized tests that follow a unique mutation…
Pontus Rehn has over 20 years of experience in commercial leadership roles in the medical device and IVD industries, including global and regional positions like VP Market Development, Chief Commercial Officer, and Director of Commercial Strategy.
Lina Said, a licensed Biomedical Scientist, brings 18 years of experience from Sahlgrenska University Hospital to her role as the Lab and Quality Manager at Simsen Diagnostics. Her primary focus is ensuring quality assurance and fostering an optimal work environment for the lab.
My Vu is currently doing a master’s degree in biotechnology and demonstrates expertise in laboratory procedures. Her previous experience includes analyzing COVID samples and conducting her bachelor’s thesis at Fraunhofer. My is analyzing all the samples that comes to the lab.
Stefan Filges, an accomplished bioinformatician with a Ph.D. in ultrasensitive sequencing, became part of Simsen Diagnostics in 2022. He played a crucial role as a co-author in the original publication of SiMSen-Seq, which was published in Nature Protocols.
Camilla Hietanen holds an M.Sc. in Business Development from the Chalmers School of Entrepreneurship. Her academic background encompasses studies in Sports & Nutrition, and she brings prior experience from various Start-ups. Within Simsen Diagnostics, her primary focus lies in Sales and Marketing.
Sign up on our maillist to gain access to your article. You can at any time unsubscribe from the list.